Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study

Pharmacological Research

Volumn 58, Issue 5-6, 2008, Pages 344-347

  Nikisch, Georg ^a   Eap, Chin B ^b   Baumann, Pierre ^b  

^a KLINIKUM FULDA   (Germany)

^b Hopital de Cery   (Switzerland)

Author keywords

ABCB1 genetic polymorphisms; Citalopram; Clinical response; CSF; Depressive patients; Plasma; Stereoselectivity

Indexed keywords

CITALOPRAM; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE INCREASE; ENANTIOMER; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MENTAL DISEASE; MORNING DOSAGE; PILOT STUDY; PLASMA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; STEADY STATE; TREATMENT RESPONSE;

ADULT; CITALOPRAM; DATA INTERPRETATION, STATISTICAL; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PILOT PROJECTS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; YOUNG ADULT;

EID: 56949103059     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.09.010     Document Type: Article

References (32)

1. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6 (1982) 277-295
2. Keller M.B. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry 61 (2000) 896-908
3. Hyttel J., Bogeso K.P., Perregaard J., and Sánchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Set 88 (1992) 157-160
4. Sánchez C., Bogeso K.P., Ebert B., Reines E.H., and Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 174 (2004) 163-176
5. Montgomery H., Loft H., Sánchez C., Reines E.H., and Papp M. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88 (2001) 282-286
6. Baumann P., Zullino D.F., and Eap C.B. Enantiomers' potential in psychopharmacology - a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 12 (2002) 433-444
7. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
8. van Asperen J., van Tellingen O., and Beijnen J.H. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 37 (1998) 429-435
9. Kusuhara H., Suzuki H., and Sugiyama Y. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J Pharm Sci 87 (1998) 1025-1040
10. Chiou W.L., Chung S.M., and Wu T.C. Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17 (2000) 903-905
11. Ebinger M., and Uhr M. ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response. Eur Arch Psychiatry Clin Neurosci 256 (2006) 294-298
12. Uhr M., Grauer M.T., and Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54 (2003) 840-846
13. Uhr M., and Grauer M.T. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 37 (2003) 179-185
14. Rochat B., Baumann P., and Audus K.L. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res 831 (1999) 229-236
15. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57 (2008) 203-209
16. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 (2004) 13-33
17. Nikisch G., Mathé A.A., Czernik A., Eap C.B., Jimenez-Vasquez P., Brawand-Amey M., et al. Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 24 3 (2004) 283-290
18. Nikisch G., Mathe A.A., Czernik A., Thiele J., Bohner J., Eap C.B., et al. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology 181 (2005) 751-760
19. Nikisch G., Ågren H., Eap C.B., Czernik A., Baumann P., and Mathé A.A. Neuropeptide Y and corticotrophin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol 8 (2005) 403-410
20. Kosel M., Eap C.B., Amey M., and Baumann P. Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. J Chromatogr Biomed Sci 719 (1998) 234-238
21. Eap C.B., Fellay J., Buclin T., Bleiber G., Golay K.P., Brocard M., et al. CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. Pharmacogenetics 14 (2004) 255-260
22. Guo S.W., and Thompson E.A. A Monte Carlo method for combined segregation and linkage analysis. Am J Hum Genet 51 (1992) 1111-1126
23. Gerloff T., Schaeffeler E., Oselin K., Meisel C., Cascorbi I., and Roots I. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healty white males. Br J Clin Pharmacol 54 (2002) 610-616
24. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69 (2001) 169-174
25. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97 (2000) 3473-3478
26. Kharasch E.D., Hoffer C., Altuntas T.G., and Whittington D. Quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J Clin Pharmacol 3 (2004) 224-233
27. Johne A., KopkeK, Gerloff T., Mai I., Rietbrock S., Meisel C., et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72 (2002) 584-594
28. Nakamura T., Sakaeda T., Horinouchi M., Tamura T., Aoyama N., Shirakawa T., et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71 (2002) 297-303
29. Illmer T., Schuler U.S., Thiede C., Schwarz U.I., Kim R.B., Gotthard S., et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemic patients. Cancer Res 62 (2002) 4955-4962
30. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70 (2001) 189-199
31. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297 (2001) 1137-1143
32. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1(P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 (2004) 13-33